BioAge Labs Q2 2025: BGE-102 on track for Phase 1, expanded APJ pipeline, strengthened discovery platform.

• BioAge Labs reports Q2 2025 financial results • Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in H2 2025 • Initial data expected by year-end • Expanded APJ agonist pipeline through option agreement and oral small molecules advancement • Strengthened discovery platform through HUNT Biobank profiling of 17,000+ samples • BioAge Labs targets metabolic diseases through human aging biology

BioAge Labs, Inc. (BioAge) has reported its second quarter 2025 financial results, highlighting significant progress in its clinical pipeline and discovery platform. The company, focused on developing therapeutic products for metabolic diseases by targeting human aging biology, announced several key milestones.

Financial Highlights
BioAge reported a net loss of $21.6 million for the quarter ended June 30, 2025, compared to a net loss of $13.6 million in the same period in 2024. Research and development expenses increased by $9.3 million, primarily due to higher costs related to licensing, discovery, and development activities for its novel apelin receptor APJ agonist programs, and IND-enabling activities for BGE-102. General and administrative expenses also increased by $2.5 million, driven by a $1.5 million increase in personnel-related expenses and a $0.9 million increase in legal fees. As of June 30, 2025, BioAge had approximately $313.4 million in cash, cash equivalents, and marketable securities, which the company estimates will be sufficient to fund operations and capital expenses through 2029 [1].

Clinical Pipeline Updates
BioAge's oral NLRP3 inhibitor, BGE-102, is on track for Phase 1 initiation in the second half of 2025. The company completed IND-enabling studies for BGE-102, positioning it for Phase 1 trials later this year, with initial single ascending dose (SAD) data anticipated by year-end. BGE-102 demonstrated significant weight loss in preclinical models both as monotherapy and in combination with the GLP-1 receptor agonist semaglutide.

The company also expanded its APJ agonist pipeline through an exclusive option agreement with JiKang Therapeutics for a novel APJ agonist nanobody, which is at least 10-fold more potent than the natural ligand of APJ. BioAge plans to advance this nanobody to the beginning of IND-enabling studies, with an option to license the program for worldwide development and commercialization.

Additionally, BioAge filed a U.S. provisional patent application for a new class of orally active, chemically distinct APJ agonists with picomolar potency and drug-like properties.

Discovery Platform Expansion
BioAge launched a collaboration with the HUNT Biobank in Norway to profile more than 17,000 individual samples from 6,000+ participants. This initiative aims to generate millions of molecular measurements tracking the transition from health to disease over decades of lifespan, fueling the company's analysis of human longevity.

Strategic Partnerships
BioAge continued to advance its multi-year research collaboration with Novartis and Lilly ExploR&D, focusing on discovering novel therapeutic targets at the intersection of aging biology and exercise physiology, and developing therapeutic antibodies targeting novel metabolic aging targets, respectively.

Forward-Looking Statements
The press release contains forward-looking statements, including plans to develop and commercialize product candidates, the timing and results of clinical trials, and risks associated with clinical trials and regulatory approvals. These statements are subject to risks and uncertainties, including the ability to develop and commercialize product candidates, the timing and results of preclinical studies and clinical trials, and risks associated with clinical trials and regulatory approvals [1].

References
[1] https://finance.yahoo.com/news/bioage-labs-reports-second-quarter-203000978.html